12.3 Immunizations & Preventive Care for Older Adults
Key Takeaways
- Immunizations are a cornerstone of primary prevention for older adults and a frequent GERO-BC application of III-A-2 disease prevention
- Prefer high-dose, adjuvanted, or recombinant influenza vaccines for adults ≥65 when available and indicated
- Age-based pneumococcal vaccination now commonly starts at age 50; zoster (RZV) is routinely recommended beginning at age 50 (2-dose series)
- RSV vaccine is recommended for all adults ≥75 and for adults 50–74 at increased risk of severe RSV; typically one lifetime dose if previously unvaccinated
- COVID-19 vaccination guidance is season/update-specific—older adults and immunocompromised persons remain high-priority groups for updated doses
Immunizations & Preventive Care for Older Adults
Quick Answer: Immunizations are high-yield primary prevention for GERO-BC. For older adults, prioritize annual influenza (prefer HD-IIV / adjuvanted / recombinant formulations at ≥65), pneumococcal vaccination (age-based recommendations now commonly begin at 50), recombinant zoster vaccine (RZV) starting at 50 (2 doses), RSV for ≥75 (and high-risk 50–74), and updated COVID-19 doses per current ACIP/CDC guidance—especially for adults ≥65 and immunocompromised persons.
This section deepens III-A-2 prevention with the vaccine knowledge gerontological nurses use daily in clinics, long-term care, home health, and hospital discharge planning. Schedules evolve; exam items test principles and priority populations more than memorizing every footnote—but you should know the major age thresholds and preferential products.
Why Vaccines Matter More with Age
Immunosenescence reduces vaccine responses and increases severity of vaccine-preventable disease. Older adults have higher rates of:
- Influenza-related hospitalization and death
- Invasive pneumococcal disease
- Herpes zoster and postherpetic neuralgia
- RSV lower-respiratory disease
- Severe COVID-19 outcomes
Nursing role: identify gaps, counsel, administer or coordinate, document, and reduce missed opportunities during every encounter—including hospitalizations and skilled-nursing stays.
Core Adult Vaccines for Aging Populations
| Vaccine | Typical older-adult recommendation pattern | High-yield nursing points |
|---|---|---|
| Influenza | 1 dose every year; for ≥65, prefer high-dose (HD-IIV3), adjuvanted (aIIV3), or recombinant (RIV3) when available | Do not delay for mild illness; LAIV not for older adults; cocooning of caregivers helps |
| COVID-19 | Updated seasonal formulation per ACIP/CDC; adults ≥65 often recommended additional/updated dosing relative to younger healthy adults | Guidance changes by season—emphasize older age and immunocompromise as priority |
| RSV | All adults ≥75: 1 dose if unvaccinated; ages 50–74: 1 dose if increased risk of severe RSV | Usually no additional doses if previously vaccinated; best timed before RSV season when possible |
| Pneumococcal | Age-based recommendation lowered to begin at 50 (PCV options such as PCV15/PCV20/PCV21 ± PPSV23 depending on product/history) | Always review prior PCV/PPSV23 history before choosing series; avoid unnecessary duplicate conjugate doses |
| Zoster (RZV / Shingrix) | 2 doses for adults ≥50; also for immunocompromised adults ≥19 per indication | Even if prior shingles or older live zoster vaccine; space doses per label (~2–6 months) |
| Td / Tdap | Tdap once if never received as adult, then Td or Tdap booster every 10 years | Wound management may need earlier dosing; pregnancy rules differ (not typical GERO focus) |
Risk-based vaccines still relevant in late life
| Vaccine | When gerontological nurses think of it |
|---|---|
| Hepatitis B | Diabetes, dialysis, certain occupational/lifestyle risks; catch-up if never vaccinated and indication present |
| Hepatitis A | Travel, chronic liver disease, other risk groups |
| MMR / Varicella | Usually not routine for older adults born before immunity cutoffs; consider for susceptible health-care personnel per notes |
Preferential Influenza Products at Age ≥65
Standard-dose egg-based vaccines are not first choice when preferential products are available. Teach patients that “any flu shot is better than none,” but preferential products improve immune response in older adults:
- High-dose inactivated influenza vaccine
- Adjuvanted inactivated influenza vaccine
- Recombinant influenza vaccine
If preferential products are unavailable, give a standard age-appropriate inactivated or recombinant vaccine rather than skip vaccination.
Pneumococcal Strategy—History First
Pneumococcal schedules are product-history dependent. Safe nursing practice:
- Obtain records (EHR, registry, pharmacy, patient card).
- Identify whether the person already received PCV13/15/20/21 and/or PPSV23.
- Follow current ACIP pathway for age ≥50 or risk-based younger adults.
- Counsel that the goal is protection against invasive disease and pneumonia—not “one shot forever” mythology if the series is incomplete.
Missed-opportunity pattern on exams: discharging an unvaccinated 70-year-old after pneumonia without addressing pneumococcal and influenza status.
RSV and COVID-19—Priority Framing
RSV: Think age ≥75 universal (if unvaccinated) and 50–74 with risk conditions (cardiopulmonary disease, immunocompromise, long-term care residence, and other ACIP-listed risks). Timing ideally before local RSV season (often late summer–early fall), but do not refuse an indicated dose solely because season has started if the person remains unvaccinated and eligible.
COVID-19: Schedules have shifted across seasons (universal vs shared decision-making nuances, extra doses for ≥65 and immunocompromised). For GERO-BC reasoning: older age and immunocompromise increase benefit; keep current with facility/public-health standing orders; document informed discussion when recommendations are individualized.
Contraindications, Precautions, and Counseling
| Situation | Approach |
|---|---|
| Anaphylaxis to a prior dose or vaccine component | Do not repeat that vaccine; refer to allergy specialist as needed |
| Moderate/severe acute illness with or without fever | Often defer until improved; mild illness is usually OK |
| Guillain–Barré history timing concerns | Individualize per ACIP footnotes; not an automatic lifelong ban for all vaccines |
| Live vaccines | Generally avoided in severe immunocompromise; older-adult influenza uses inactivated/recombinant options |
| Fear of side effects | Expect local arm pain (especially RZV); prep with analgesia plan and schedule around important events |
Use motivational interviewing: acknowledge concerns, share age-specific risk of disease, and offer same-day vaccination when possible.
Preventive Care Beyond the Needle
Immunizations sit inside a broader preventive visit:
- Medication review (prevent iatrogenic disease)
- Fall risk and exercise referral
- Vision/hearing checks affecting safety
- Dental/oral health impacting nutrition and aspiration risk
- Advance-care planning while the older adult is stable (prevents crisis discord—not a vaccine, but preventive systems care)
- Skin cancer vigilance and sun safety education
- Tobacco and alcohol counseling
| Setting | Closing the gap |
|---|---|
| Primary care / geriatrics clinic | Standing orders; registry outreach |
| Hospital | Offer indicated vaccines before discharge when stable |
| Long-term care | Facility programs for influenza/COVID/pneumococcal/RSV per policy and ACIP |
| Home health | Coordinate pharmacy/clinic administration; educate caregivers |
Documentation Essentials
Record vaccine name, dose, site/route, lot/expiry when required, VIS date, and patient response. Update the immunization information system when applicable. Clear documentation prevents duplicate dosing and supports quality measures tied to older-adult immunization rates.
Immunization excellence on GERO-BC looks like proactive gap closure + age-appropriate product choice + respectful counseling—not waiting for the older adult to ask.
For routine annual influenza vaccination in adults aged 65 and older, which approach best matches current preferential guidance?
Which statement about recombinant zoster vaccine (RZV) in older adults is correct?
An unvaccinated 78-year-old without listed immunocompromise asks about RSV vaccination. What is the best counseling point?
A 70-year-old is discharged after community-acquired pneumonia with no documented pneumococcal vaccination. What is the best gerontological nursing action?